FY2026 EPS Forecast for Harvard Bioscience Lifted by Analyst

Harvard Bioscience, Inc. (NASDAQ:HBIO – Free Report) – Investment analysts at Sidoti increased their FY2026 earnings estimates for shares of Harvard Bioscience in a note issued to investors on Wednesday, November 11th. Sidoti analyst J. Sidoti now expects that the medical instruments supplier will post earnings per share of ($2.37) for the year, up from their previous forecast of ($2.44). The consensus estimate for Harvard Bioscience’s current full-year earnings is ($2.44) per share.

Other analysts have also recently issued reports about the stock. Benchmark upped their target price on shares of Harvard Bioscience from $6.00 to $7.50 and gave the company a “speculative buy” rating in a research report on Wednesday, August 12th. Stonex Financial downgraded Harvard Bioscience from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, November 11th. StoneX downgraded Harvard Bioscience from a “speculative buy” rating to a “hold” rating in a research report on Wednesday, November 11th. Zacks Research began coverage on shares of Harvard Bioscience in a research note on Tuesday, November 3rd. They issued a “hold” rating on the stock. Finally, Weiss Ratings upgraded shares of Harvard Bioscience from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, November 9th. One equities research analyst has rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $6.75.

Get Our Latest Stock Report on Harvard Bioscience

Harvard Bioscience Stock Down 3.6%

Shares of HBIO opened at $8.68 on Friday. The business’s 50 day simple moving average is $8.41 and its 200-day simple moving average is $6.66. Harvard Bioscience has a 1 year low of $4.00 and a 1 year high of $10.20. The company has a quick ratio of 0.86, a current ratio of 1.76 and a debt-to-equity ratio of 7.28.

Harvard Bioscience (NASDAQ:HBIO – Get Free Report) last announced its quarterly earnings results on Tuesday, November 10th. The medical instruments supplier reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.27. Harvard Bioscience had a negative net margin of 13.20% and a negative return on equity of 43.94%. The business had revenue of $22.20 million for the quarter, compared to analysts’ expectations of $21.80 million.

Institutional Investors Weigh In On Harvard Bioscience

An institutional investor recently bought a new stake in Harvard Bioscience stock. Citadel Advisors LLC acquired a new position in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO – Free Report) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 13,251 shares of the medical instruments supplier’s stock, valued at approximately $81,000. Citadel Advisors LLC owned about 0.29% of Harvard Bioscience at the end of the most recent reporting period. Hedge funds and other institutional investors own 80.87% of the company’s stock.

Harvard Bioscience Company Profile

(Get Free Report)

Harvard Bioscience, Inc. develops, manufactures and sells scientific instruments and equipment used in life science research. Its products support work in areas such as physiology, electrophysiology and preclinical research, and are used by academic and government institutions, biotechnology and pharmaceutical companies, and contract research organizations. The company’s offerings include laboratory instruments, equipment and related consumables, including systems for measuring biological activity and studying tissues, organs and cells.

Featured Stories

Earnings History and Estimates for Harvard Bioscience (NASDAQ:HBIO)

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.